Koenig, Wolfgang http://orcid.org/0000-0002-2064-9603
Lorenz, Elke S.
Beier, Lea
Gouni-Berthold, Ioanna
Funding for this research was provided by:
Novartis
Technische Universität München
Article History
Received: 7 February 2023
Accepted: 26 June 2023
First Online: 21 August 2023
Declarations
:
: Prof. Koenig, outside the submitted work, reports consulting fees from AstraZeneca, Novartis, Pfizer, The Medicines Company, DalCor, Kowa, Amgen, Corvidia Therapeutics, Daiichi-Sankyo, Genentech, Novo Nordisk, Esperion, OMEICOS, New Amsterdam Pharma, TenSixteen Bio; speaker honoraria from Amgen, Novartis, Berlin-Chemie, Sanofi, AstraZeneca, and Bristol-Myers Squibb; and grants and non-financial support from Abbott, Roche Diagnostics, Dr. Beckmann Pharma, and Singulex. Dr. Lorenz reports speaker honoraria from Amgen, Novartis, and Sanofi outside the submitted work. Dr. Beier is an employee of Novartis Pharma GmbH. Prof. Gouni-Berthold reports personal fees from Amgen, Amarin, Akcea, Daiichi-Sankyo, Novartis, Ultragenyx, and Sanofi outside the submitted work.
: The authors contributed to the concept, design, and initial draft of the work, to the analysis and interpretation of the data, performed a critical revision of the manuscript for important intellectual content and decided to submit it for publication. Novartis funded the procurement of anonymized data from the Insight Health™ Patient Insight Tool and the professional medical writing support.